Monday, November 16, 2026
7.8 C
London

F.D.A. Rejects Ivonescimab, Closely Watched Lung Cancer Drug From China

The Food and Drug Administration has rejected a closely watched lung cancer drug developed in China. The treatment, called ivonescimab, had drawn intense attention from researchers and investors. Its rejection marks a notable setback for the drug’s developer.

Ivonescimab had become a symbol of China’s rapid rise in drug development. The therapy was seen as a potential breakthrough for patients with certain lung cancers. Many observers viewed it as a test of whether Chinese-made drugs could win U.S. approval.

The agency’s decision was announced on November 15, 2026. Specific reasons for the rejection were not immediately detailed in the report. The developer has not publicly outlined its next steps.

The drug targets lung cancer through a dual-action mechanism. It combines immune checkpoint blockade with an anti-angiogenic approach. This design had shown promising results in earlier clinical trials.

China’s biotech sector has expanded quickly in recent years. Companies there now produce a growing share of innovative cancer therapies. Ivonescimab was among the most prominent candidates to seek U.S. market entry.

The rejection raises questions about the path for Chinese-developed drugs in the United States. Regulatory standards and clinical data requirements remain rigorous. Firms seeking approval must meet the same benchmarks as domestic developers.

Patients and clinicians had monitored the drug’s progress closely. Some had hoped for a new option against hard-to-treat lung cancers. The FDA’s decision delays that possibility for now.

The developer is expected to review the agency’s feedback. Additional trials or data may be required before a resubmission. The timeline for any new filing remains uncertain.

Hot this week

Nvidia Espionage Report Shadows Trump-Xi Trade Talks

President Trump has signaled he will not raise U.S....

Lutnick Pushed to Weaken AI Chip Export Rules Tied to His Former Firm’s Data Center Clients

Commerce Secretary Howard Lutnick has pushed to weaken proposed...

Chris Van Hollen Says His Senate Democratic Leadership Challenge to Chuck Schumer Is Gaining Support

Senator Chris Van Hollen of Maryland said Sunday he...

8 Takeaways From a Big Democratic Gathering in Denver: Democrats in Array

Democrats gathered in Denver for a major party event...

Lutnick Moves to Ease Chip Export Rules Tied to His Former Firm’s Clients

Commerce Secretary Howard Lutnick has moved to soften chip...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img